1 Ipsos’ COVID-19 diagnostics and therapeutics consumer study is an ongoing syndicated survey conducted among consumers on the Ipsos Global Advisor online platform. Results cited in this article were based on research conducted between Jul 3 and 13 last year among 2,003 consumers aged 18 to 74 in Singapore. The full study was conducted among more than 60,000 adults in 29 countries. The recruitment process aims to ensure a nationally representative base for the samples collected. All data were collected online. Data Ipsos 2024, all rights reserved.

2 Consumers at high risk of getting seriously ill from COVID-19 were defined as those who were 60 or older, or, current or previous smokers, or, aged 18 or over with at least one comorbidity (of those included in survey).

3 The rating scale used in the study ranges from 1 to 7, where a score of 1 indicates “do not agree at all” and a score of 7 indicates “completely agree”.

4 The rating scale used in the study ranges from 1 to 7, where a score of 1 indicates “not at all aware” and a score of 7 indicates “very aware”.

This article is sponsored by Pfizer Singapore. The opinions expressed in this article are solely attributable to the expert(s)/ speaker(s)/participant(s) appearing in therein. This material is intended for educational/disease awareness purpose only and is not intended to replace consultation with the healthcare professional. For any further information please consult your healthcare professional. Please refer to the latest Singapore Ministry of Health Guideline for oral antiviral treatment eligibility criteria.

References available upon request.

Source link